Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$9.88
+5.3%
$8.62
$5.90
$28.18
$971.61M2.212.93 million shs5.56 million shs
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
$0.34
$0.17
$0.74
$18.10M0.6494,622 shs932,700 shs
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
$21.99
$21.98
$8.37
$23.11
$570.90M1.421.10 million shsN/A
Quotient Limited stock logo
QTNT
Quotient
$0.44
$0.18
$105.20
$980K2.32437,886 shs5.81 million shs
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$33.97
$33.70
$20.35
$34.38
$1.50B0.23973,737 shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+5.33%+3.24%+41.34%+35.34%-56.03%
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
0.00%0.00%0.00%0.00%0.00%
Quotient Limited stock logo
QTNT
Quotient
0.00%0.00%0.00%0.00%0.00%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4.655 of 5 stars
4.33.00.04.71.42.50.6
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
N/AN/AN/AN/AN/AN/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
N/AN/AN/AN/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.65
Moderate Buy$33.37237.74% Upside
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
0.00
N/AN/AN/A
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
0.00
N/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
0.00
N/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OXFD, VIVO, QTNT, NYMX, and NTLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$7.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/3/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $54.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00 ➝ $7.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/20/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/19/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/12/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $45.00
5/9/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.00
5/9/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$68.00 ➝ $68.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$57.88M17.68N/AN/A$8.56 per share1.15
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/AN/AN/AN/A($0.01) per shareN/A
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
$73.71M7.75$0.02 per share1,408.78$8.08 per share2.72
Quotient Limited stock logo
QTNT
Quotient
$38.51M0.00N/AN/A($56.17) per share0.00
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$333.02M4.49$1.78 per share19.13$8.41 per share4.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
-$6.58M-$0.04N/AN/AN/AN/A-1,589.50%-117.25%N/A
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
-$1.81M-$0.05N/AN/AN/A-30.51%-8.39%-7.63%N/A
Quotient Limited stock logo
QTNT
Quotient
-$125.13M-$53.21N/AN/AN/A-413.55%N/A-88.21%N/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$42.46M$0.9735.02N/A12.70%16.74%13.09%N/A

Latest OXFD, VIVO, QTNT, NYMX, and NTLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/AN/AN/AN/AN/A
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
N/AN/AN/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
N/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
4.90
4.90
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
N/A
0.19
0.19
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
N/A
15.96
14.85
Quotient Limited stock logo
QTNT
Quotient
N/A
1.79
1.36
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.07
3.63
2.46
CompanyEmployeesShares OutstandingFree FloatOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600103.58 million100.37 millionOptionable
Nymox Pharmaceutical Co. stock logo
NYMX
Nymox Pharmaceutical
390.51 million41.64 millionOptionable
Oxford Immunotec Global PLC stock logo
OXFD
Oxford Immunotec Global
27325.96 millionN/ANot Optionable
Quotient Limited stock logo
QTNT
Quotient
4262.58 million2.31 millionOptionable
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
70244.01 million43.00 millionOptionable

Recent News About These Companies

Meridian Bioscience Inc (VIVO)
India's smartphone mkt grows 6%, Vivo tops
Precision BioSciences Launches First Hepatitis B Gene-Editing Trial
Meridian Growth Legacy MERDX
Biomerica, Inc. (BMRA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$9.88 +0.50 (+5.33%)
Closing price 07/1/2025 04:00 PM Eastern
Extended Trading
$10.01 +0.13 (+1.32%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Nymox Pharmaceutical stock logo

Nymox Pharmaceutical NASDAQ:NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Oxford Immunotec Global stock logo

Oxford Immunotec Global NASDAQ:OXFD

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Quotient stock logo

Quotient NASDAQ:QTNT

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Meridian Bioscience stock logo

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.